Pediatric Neuroblastoma Treatment Market - Snapshot

The global pediatric neuroblastoma treatment market is projected to reach US$ 1.3 Bn by 2026, expanding at a high CAGR during the forecast period. Rise in R&D expenditure, increase in incidence of neuroblastoma among children, and rise in awareness about available treatments are the factors anticipated to augment the global market during the forecast period. Moreover, advancement in technology and improvement in health care infrastructure are expected to propel the global pediatric neuroblastoma treatment market during the forecast period. However, high research and development cost associated with cancer therapy is likely to hamper the growth of the market. 

pediatric neuroblastoma treatment market

The global pediatric neuroblastoma treatment market has been segmented based on therapy type and distribution channel. In terms of therapy type, the market has been classified into immunotherapy, chemotherapy, and others. The chemotherapy segment held leading market share in 2017. The segment is projected to expand at the highest CAGR during the forecast period. This is attributed to effectiveness of chemotherapy drugs in neuroblastoma treatment. Moreover, chemotherapy is the treatment of choice to slow down disease progression and reduce symptoms. It can also be combined with other treatments such as radiation therapy or surgery for more effective results.

Based on distribution channel, the global pediatric neuroblastoma treatment market has been categorized into hospital pharmacies and retail pharmacies & drug stores. The hospital pharmacies segment dominated the market in 2017 and is expected to retain its leadership position in terms of market share during the forecast period. This is due to high preference to hospital pharmacies for purchasing drugs prescribed for cancer treatment. Moreover, hospital pharmacies ensure drug safety and accurate dosage of drugs as per treatment prescription.

In terms of region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, and Rest of the World. North America dominated the global market in 2017. According to American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the U.S. each year. This number has been stagnant for several years. Additionally, high cost of therapy, technologically advanced products, improved health care infrastructure, and better reimbursement plans are the major factors contributing to the region’s dominance of the global market. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period owing to improving health care infrastructure and rise in public investment in research and technological advancements in countries such as China and India.

Major players operating in the global pediatric neuroblastoma treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG. These players are expanding their product portfolios through mergers and acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies, and by offering technologically advanced products.

Pediatric Neuroblastoma Treatment Market - Overview

This report by Transparency Market Research analyzes the global pediatric neuroblastoma treatment market for the period between 2018 and 2026. An in-depth market assessment has been made, which offers readers accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various products as well as new players planning to enter this market.

The global pediatric neuroblastoma treatment market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape by major players operating in this market along with their shares (value %) of the global pediatric neuroblastoma treatment market for 2017. The report also provides detailed company profiles of emerging market players operating in the global market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global pediatric neuroblastoma treatment market. These factors are likely to aid stakeholders establish a strong foothold in the global market. Furthermore, the overview section comprises market attractiveness analysis, global market analysis, and forecast of the global pediatric neuroblastoma treatment market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global pediatric neuroblastoma treatment market has been segmented based therapy type and distribution channel. In terms of therapy type, the global market has been classified into immunotherapy, chemotherapy, and others. Based on distribution channel, the global pediatric neuroblastoma treatment market has been categorized into hospital pharmacies and retail pharmacies & drug stores.

In terms of region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global pediatric neuroblastoma treatment market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global pediatric neuroblastoma treatment market that is expected to assist new companies establish their presence and expanding their share in the market. The report concludes with the company profile section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments.

Competitive Landscape

Major players operating in the global pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG.

The global pediatric neuroblastoma treatment market has been segmented into:

  • Global Pediatric Neuroblastoma Treatment Market, by Therapy Type
    • Immunotherapy
    • Chemotherapy
    • Others
  • Global Pediatric Neuroblastoma Treatment Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies & Drug Stores
  • Global Pediatric Neuroblastoma Treatment Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Rest of Europe
    • Rest of the World
.